Navigation Links
InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
Date:2/17/2010

regimens of the Phase 2b study of un-boosted RG7227 plus SOC are expected to be reported late in the first quarter or early in the second quarter of 2010.  
  • A Phase 2b study of ritonavir-boosted RG7227 plus SOC is expected to begin in Q3 of 2010.  This study replaces the previously planned 24-week un-boosted regimens of the on-going Phase 2b triple combination study.
  • InterMune and Roche today reported that the next step in the INFORM direct antiviral agent (DAA) program is planned to be a study combining RG7128 with ritonavir-boosted RG7227 involving treatment durations of at least 12 weeks and evaluating sustained virologic response (SVR).  The ritonavir-boosted DAA study to evaluate SVR may begin in the second half of 2010; the exact timing will be based on emerging data from the on-going studies.  The companies also announced today that given the importance of generating longer-term safety and SVR data for ritonavir-boosted RG7227 in combination with RG7128, the previously planned INFORM-2 four-week study will not be conducted.  

  • Financial:

    • On January 29, 2010, InterMune completed a public offering of 8,050,000 shares of common stock, including the underwriters' over-allotment, with net proceeds to the company of $106.8 million (after payment of the underwriting discounts and commissions, and expenses).

    Fourth Quarter and Full-Year 2009 Financial Results (Unaudited)

    InterMune reported total revenue in the fourth quarter of 2009 of $6.6 million, compared with $7.4 million in the fourth quarter of 2008, reflecting lower off-label physician prescriptions of Actimmune® (gamma interferon-1b) for the treatment of IPF, which InterMune does not promote.  Total revenue for the fu
    '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related medicine technology :

    1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
    2. InterMune Announces Start of Phase 1b Trial of ITMN-191
    3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
    4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
    5. InterMune Announces Progress on Pirfenidone in IPF
    6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
    7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
    8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
    9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
    10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
    11. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/29/2014)... SAN DIEGO , 29 septembre ... désignée Daiichi Sankyo) (TSE : 4568) et Ambit Biosciences ... d,un accord de fusion définitif en vertu duquel ... actions ordinaires en circulation d,Ambit Biosciences à 15 ... d,une offre publique d,achat qui sera suivie d,une ...
    (Date:9/29/2014)...  Bob Pack, who lost his two young children ... Medical Association to immediately cease airing a television ad ... Mercury News called "shamelessly deceptive" and of which the ... believe about the measure is wrong." ... that doctors check California,s existing ...
    (Date:9/29/2014)... Sept. 29, 2014  Volcano Corporation (Nasdaq: ... improving patient and economic outcomes on a global ... coronary and peripheral visualization, physiology diagnostics and therapies, ... Board of Directors from Engaged Capital, LLC.  The ... Volcano welcomes the perspectives of its ...
    Breaking Medicine Technology:Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 2Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 3Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 4Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 5Volcano Issues Statement Regarding Letter From Engaged Capital 2Volcano Issues Statement Regarding Letter From Engaged Capital 3
    ... studied the treatment of pregnant women with hepatitis B virus ... study concluded that both the mothers benefited from treatment and ... weeks postbirth. The study presenter and co-investigator Calvin ... as hepatitis B is difficult to eradicate and currently there ...
    ... POINT, Calif., Nov. 1, 2010 The Global ... organization that aims to raise awareness about the ... 7,000 Bracelets for Hope™ campaign. The 7,000 Bracelets ... to an estimated 7,000 different chronic, life-threatening and ...
    Cached Medicine Technology:Telbivudine Given to Mothers With Hepatitis B Reduces Infection Rate in Infants 2Telbivudine Given to Mothers With Hepatitis B Reduces Infection Rate in Infants 37,000 Bracelets For Hope™ - A Rare Disease Awareness Campaign 27,000 Bracelets For Hope™ - A Rare Disease Awareness Campaign 3
    (Date:9/30/2014)... Seattle, WA (PRWEB) September 30, 2014 ... Intelligence, proudly announced today that the Department of ... Office as its Enterprise End User Business ... to better support our nation’s veterans by enabling ... obtained through BI Office’s powerful enterprise analytics and ...
    (Date:9/30/2014)... September 30, 2014 “Biology and ... Bryan W. Brickner, “and it’s about naming rights.” ... Science , new on the Bryan William Brickner ... the National Institutes of Health (PubMed). The post ... sleep disturbances, REM transitions, aging with THC, the ...
    (Date:9/30/2014)... A trailblazer at heart, Dr. Scott Katzman stays ... breakthroughs in spine repairs. His newest appreciation has been ... in which he has implanted the Mobi-C Artificial Disc ... art and mimic normal human disc motion. Dr. Katzman goes ... to be an exceptional replacement device for failing fusions. Patients ...
    (Date:9/30/2014)... 3M has added four new thin VHB products to ... 5906 , 3M 5907 , 3M 5908 , ... create the strongest bond possible to a wide range of ... difficult surfaces such as paints, low surface energy plastics, and ... are designed specifically for electronic device engineers and electronics manufacturers. ...
    (Date:9/30/2014)... RI (PRWEB) September 30, 2014 Dogs are ... Oftentimes, this involves spending time in the car travelling from ... canines have free run of the vehicle; however, this is ... owner as well. Royal Flush Havanese shares with ... always be routine practice. , There are many ways a ...
    Breaking Medicine News(10 mins):Health News:U.S. Department of Veterans Affairs Takes Its Analytic Capabilities to the Next Level with BI Office from Pyramid Analytics 2Health News:Homeostasis: Publius’ Sleep Political Cannabinoid Science ~ New on the Bryan William Brickner Blog 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 2Health News:3M Releases New VHB™ Thin Foam Tapes as the Ultimate Electronics Bonding Solution 3Health News:Royal Flush Havanese Offers Tops On the Importance of Restraining Dogs In Cars 2Health News:Royal Flush Havanese Offers Tops On the Importance of Restraining Dogs In Cars 3
    ... and ,Samantha Who?, to be Honored at Donate Life Film ... June 5 On June 13, Donate Life Hollywood will ... "Samantha Who?" with its first annual Inspire Award. This honor, ... be presented at the culmination of the daylong Donate Life ...
    ... evident with seniors, researchers say , FRIDAY, June 5 (HealthDay ... new generation of video games that require users to get ... bit more fit. , New research suggests that several exercise-based ... equal to that of light jogging. , And seniors in ...
    ... Joseph F. Finn, Jr., C.P.A. ("Finn") announced today ... Cancer Research Ltd., Brussels Branch. The statement is quoted ... product candidate, GCS-100, is a carbohydrate molecule which inhibits the ... a broad range of human cancers. Prospect reported that ...
    ... show, , FRIDAY, June 5 (HealthDay News) -- One reason ... not that interesting. But what if you could dance your ... suggest that you just might be able to do that. ... meeting in Seattle, one study found that salsa dancing could ...
    ... region are ready to prescribe and dispense medications electronically , ... of Spain and IBM (NYSE: IBM ) have ... where health centres and pharmacies are now computerised and able ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090416/IBMLOGO ...
    ... are experiencing onerous fatigue four months after the infarction. The ... infarction as a sign of chronic illness, those who experience ... that the illness has a large impact on their life. ... Sahlgrenska Academy, University of Gothenburg, Sweden. Just over 200 ...
    Cached Medicine News:Health News:ABC-TV Gets It Right According to Organ Donation Community 2Health News:Interactive Video Games Offer Exercise Benefits 2Health News:Interactive Video Games Offer Exercise Benefits 3Health News:Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Inc's. GCS-100 Molecule 2Health News:Finding Fitness on the Dance Floor 2Health News:Finding Fitness on the Dance Floor 3Health News:Spain's Regional Extremadura Government Launches Electronic Prescription System With IBM 2Health News:Fatigue common after myocardial infarction 2
    ... Aplicare's Saturated Swabsticks are packaged ... Each 4 inch Swabstick is saturated ... solution. Each package is terminally sterilized, ... the patient. It acts as a ...
    ... Antiseptic Antibacterial that does not ... 30 seconds, destroys over 99% ... for cleansing of minor wounds, ... disinfection of personal utensils and ...
    ... professional degerming, pre-op and post-op procedures. ... quaternary and substituted phenolic active ingredients ... and surfactants. Unprecedented efficacy on all ... 30 seconds. Techni-Care represents a new ...
    Aplicare's disposable 1-ounce pouches are designed for individual application and are ideal for reducing waste. They are used in nursing homes, home healthcare settings, blood banks, laboratories, em...
    Medicine Products: